EUVIMEDEUVIMED entdecken
Open Access

Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors

Yuta Hikichi iD, Jonathan R Grover iD, Alicia Schäfer iD, Walther Mothes iD, Eric O Freed

Science Advances · 2024-03 · 10 (9)

DOI: 10.1126/sciadv.adn0042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2024-03. Verfasst von Yuta Hikichi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Virus-Cell Interaction Section, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA. Hauptthemen laut MEDLINE: HIV Integrase Inhibitors, HIV-1, HIV Integrase. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

People living with human immunodeficiency virus (HIV) receiving integrase strand transfer inhibitors (INSTIs) have been reported to experience virological failure in the absence of resistance mutations in integrase. To elucidate INSTI resistance mechanisms, we propagated HIV-1 in the presence of escalating concentrations of the INSTI dolutegravir. HIV-1 became resistant to dolutegravir by sequentially acquiring mutations in the envelope glycoprotein (Env) and the nucleocapsid protein. The selected Env mutations enhance the ability of the virus to spread via cell-cell transfer, thereby increasing the multiplicity of infection (MOI). While the selected Env mutations confer broad resistance to multiple classes of antiretrovirals, the fold resistance is ~2 logs higher for INSTIs than for other classes of drugs. We demonstrate that INSTIs are more readily overwhelmed by high MOI than other classes of antiretrovirals. Our findings advance the understanding of how HIV-1 can evolve resistance to antiretrovirals, including the potent INSTIs, in the absence of drug-target gene mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV Integrase InhibitorsHIV-1HIV IntegraseHumansRaltegravir PotassiumMutation

Substanzen

Raltegravir PotassiumHIV Integrase InhibitorsHIV Integrase

Autor:innen und Institutionen

  • Virus-Cell Interaction Section, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
  • Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT, USA.

ORCID-Profile: Yuta Hikichi, Jonathan R Grover, Alicia Schäfer, Walther Mothes

Förderung

  • NIAID NIH HHS

Zitieren

APA

Hikichi, Y., Grover, J. R., Schäfer, A., Mothes, W., & Freed, E. O. (2024). Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors. Science Advances, 10(9). https://doi.org/10.1126/sciadv.adn0042

Vancouver

Hikichi Y, Grover JR, Schäfer A, Mothes W, Freed EO. Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors. Science Advances. 2024;10(9). doi:10.1126/sciadv.adn0042

BibTeX
@article{Hikichi2024,
  author = {Hikichi, Yuta and Grover, Jonathan R and Schäfer, Alicia and Mothes, Walther and Freed, Eric O},
  title = {Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {9},
  doi = {10.1126/sciadv.adn0042}
}
Kostenlos starten →